...a few facts you may wish to consider...
AVXT: AVAX Technologies, Inc. , the facts as I see them ... a viewpoint.
-"AVAX Poised to Become a Leading Individualized Cell and Gene Therapy Company."
(Facilities in North America, Europe, & Australia.)
-The autologous cancer vaccine has 55% survival rate in stage III metastatic melanoma
patients (compared to 22% with no post surgical treatment, and a survival rate of
about 33% with a protocol of AlphaInterferon, the current "Gold Standard).
-A 5 year survival rate of patients over 50 was 71%, versus 47% for those under 50.
-Significantly longer 5-year survival rate of 71%, versus 49% for those who did not show
the DTH response(welt at injection spot).
-09/27/2000: recieved ORPHAN DRUG STATUS for O-VAX cancer vaccine. Already has Orphan Drug status for M-VAX in pivotal registration now.
-A total of 25 cancer trial sites available here in USA.
-Ten years of data; and all data was reported, nothing was deleted or held back at all.
-The vaccine is virtually NON TOXIC.
-Commercialized and selling cancer vaccine to paying patients in Australia right now, (patients will travel.)
-Plans are in process to open up business soon in Netherlands. (by the end of 2001)
-Plans are in process to open up business soon in Germany. (by the end of 2001)
-Plans are in the works on doing business in Japan. (University of Tokyo is doing cancer trials for no cost!)
-Launch of MVAX in New Zealand planned soon!
-Very close to patent approval for the other 3 cancer fighting compounds. (O-VAX, B-VAX, L-VAX).
-The Company also anticipates development of similar technology for the treatment of
other cancers, which may include prostate, lung and colorectal cancer.
-Patent filings for the TOPOISMERASE INHIBITOR and cancer fighting ANTI-ESTROGEN COMPOUNDS expected.
-Company is expecting to file an IND for TOPOISOMERASE INHIBITORS with the FDA during 2000.
-The company moved to the national NASDAQ market on October 9, 2000. (FLOAT: 10.6 mil.)!!
-M-VAX blows away the current gold standard melanoma treatment, no contest imo.
-Genopoietic is now a Wholly Owned Subsidiary of AVAX Technologies, as of: 08/24/2000. biz.yahoo.com
-GENOPOIETIC recently in genetics news: "supplies RETROVIRAL VECTOR for bubble babies." (STEM CELL play now!)
-AVAX Technolgies, Inc. has Acquired All Patent Rights from the Cell and Gene
Therapy Laboratory of Dr. David Klatzmann at UPMC avxtinvestors.homestead.com
-Genopoietic technologies are autologous chondrocytes for the repair of damaged
cartilage AND thymidine kinase (TK) suicide gene technology for the treatment of graft-versus-host-disease (GVHD), cancer and other indications.
-Genopoetic's primary products include therapies for joint repair, bone marrow
transplantation, autoimmune diseases and organ transplantation.
-PIPELINE: add the great AVXT pipeline to that of Genopoietics: that should make
AVXT the global leader in the personalized treatment field (13 products).
1:Cartilage repair ,2:joint repair, 3:bone marrow transplants,4:auto immune deseases,
5:multiple sclerosis, 6:gene therapy for cancer, 7:organ transplants, 8:anticancer
topoisomerase inhibitor compounds, 9:cancer fighting anti-estrogen compounds,
10:M-VAX for melonoma, 11:O-VAX for ovarian cancer, 12:L-VAX for leukemia,
13:B-VAX for breast cancer. (Eight cell or gene therapy products in clinical testing.)
-MVAX, OVAX and the CHONDROCYTES bringing in cash in a number of European Markets soon.
-AVXT only a 180 million dollar MARKET CAP.
-CEO said in interview that he expects news on patent approvals for his 2 other cancer drugs.
-AVXT current cash position is over 30 million dollars so money is not an issue.
-Expect to hear more on M-VAX sales; expect to hear more on O-VAX , B-VAX and L-VAX.
-M-VAX is in late stage trial, pivotal trial registration is the last stop before APPROVAL.
-Expect to hear a few more cancer applications for our vaccine (other types of cancer).
-SMALL MARKET CAP, HUGE PIPELINE (go ahead and compare it to others!).
-AVAX CEO stated they are looking aggessively into the possibility of doing the
vaccine for earlier stage patients too.
-The company stated there have been no regulatory inquiries or compliance concerns, zero, none.
-Start of clinical development of topoisomerase inhibitors planned for later this year.
-Start of clinical development in one additional cancer indication planned this year.
-Extension of M-VAX to earlier stage patients in progress in low-dose arm of current trial.
-Extension of M-VAX to patients in Stage 4 MM in progress.
-AVAX Technoloigies, Inc. has three CORE TECHNOLOGIES: the AC Vaccine technology,
topoisomerase inhibitors and anti-estrogens.
-"Genopoietic enhances AVAX's pipeline of products within oncology and beyond, to include
therapies for joint repair, bone marrow transplantation, autoimmune diseases, such as
multiple sclerosis, and even organ transplantation." ~from SEC filing S-8.
-INDs for various GENE THERAPIES in 2001 are planned: in liver cancer and leukemia.
-Expect first quarter of 2001 NDA for autologous CHONDROCYTES in Europe,approval!
-CHONDROCYTES Market:40'000 to 50'000 surgical procedures each year in underserved Europe: cost @5'000 USD/treatment in which CHONDROCYTES could be used.
-AVAX is currently in talks with companies regarding partnerships to market and distribute Avax's drugs.
-M-VAX has received ORPHAN DRUG STATUS IN THE U.S. The AC Vaccine technology
is also being evaluated in a multi-center Phase 2 trial in OVARIAN CANCER (O-Vax™),
a Phase 1/2 equivalent trial in BREAST CANCER with The University of Tokyo, and a
Phase 1/2 trial in ACUTE MYELOGENOUS LEUKEMIA (L-Vax™) at the MD Anderson Cancer Center.
The AC Vaccine™ technology was invented by David Berd, M.D., professor of medicine at
the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia.
-M-VAX is produced through a contract manufacturing agreement with Bioenterprises Pty. Ltd.
for Australian patients; M-VAX is also produced in the USA at a manufacturing facility
in Penns.
-Audio lecture by Dr. Berd (the inventor): avax-tech.com :AVAX Technologies,Inc.
-Develop and commercialize: it's acquired the exclusive worldwide rights to a series of
compounds for the potential treatment of cancer and other infectious diseases from Rutgers.
-The Company has acquired the exclusive worldwide rights to another series of
compounds for the potential treatment of cancer from Texas A&M.
-The Company leased a laboratory research facility in Albany, New York for advancing
research on the AC Vaccine technology.
-AVAX Technologies just completed a 25 million dollar private placement, cash is not an issue,
plans are underway more even more capital for the distant future (which is very bright!)
-World's First Ever TUMOR CELL BANK!
"NEWS FLOW" is potentially very explosive in the coming 365 days and beyond!
A partnership in Europe would be interesting! hmmm.
avax-tech.com or Phone (816) 960-1333 :Investor Relations:
Rich Rainey. or... call the CEO: Jeffrey Jonas: (816) 960-1333.
***Audio interview w/CEO; Jeffrey Jonas at eviewinvestor.com
messages.yahoo.com
:*****AVAX Tech. in this conf. on SEPTEMBER 18-19, 2000 from 9:00 to 9:30am.******
biz.yahoo.com
:Announcement of GENOPOIETIC aquisition.
stockhouse.com
:AVXT getting noticed. |
